Radiation therapy for T1 and T2 prostate cancer: Prostate-specific antigen and disease outcome
- 31 March 1995
- Vol. 45 (3) , 476-483
- https://doi.org/10.1016/s0090-4295(99)80019-3
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Definitive therapy for prostate carcinoma: Mayo Clinic results at 15 years after treatmentThe British Journal of Radiology, 1994
- Radical Radiation Therapy in the Management of Prostatic Adenocarcinoma: The Initial Prostate Specific Antigen Value as a Predictor of Treatment OutcomeJournal of Urology, 1994
- SERUM PSA AFTER ANATOMIC RADICAL PROSTATECTOMYUrologic Clinics of North America, 1993
- Prognostic factors in prostate cancer: Analysis of 874 patients treated with radiation therapyCancer, 1993
- Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostateUrology, 1993
- Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapyCancer, 1993
- Prostate Specific Antigen after External Beam Radiotherapy for Prostatic Cancer: FollowupJournal of Urology, 1993
- Is Prostate Specific Antigen of Clinical Importance in Evaluating Outcome after Radical ProstatectomyJournal of Urology, 1993
- Prostate Specific Antigen Levels After Radical Prostatectomy in Patients with Organ Confined and Locally Extensive Prostate CancerJournal of Urology, 1992
- The role of radiation therapy in stages A2 and B adenocarcinoma of the prostateInternational Journal of Radiation Oncology*Biology*Physics, 1988